DSGN vs WVE
DSGN: A clinical-stage biotechnology company pioneering a novel class of small-molecule GeneTAC therapeutics to treat serious genetic diseases by modulating gene expression. WVE: A clinical-stage biotechnology company developing a versatile, multimodal RNA medicine platform to treat rare and common diseases without the need for complex delivery vehicles like lipid nanoparticles.
Side-by-side fundamentals
| Metric | DSGN | WVE | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $11.78 | $5.74 | |
| Market cap as of 2026-07-23 | $736M | $1.1B | |
| PEG as of 2026-07-23 | -0.50 | -0.11 | DSGN lower |
| Net margin as of 2026-07-23 | -3600.0% | -255.7% | WVE higher |
| Operating margin as of 2026-07-23 | -3621.7% | -274.2% | WVE higher |
| ROE as of 2026-07-23 | -33.1% | -55.7% | DSGN higher |
| ROA as of 2026-07-23 | -31.3% | -42.8% | DSGN higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-23 | n/a | -31.6% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +127.1% | |
| Beta as of 2026-07-23 | 1.63 | -1.33 | |
| 1-year return as of 2026-07-22 close | +197.8% | -27.6% | DSGN higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.